Any current/future new fundraising through debt or equity?

MPS Limited has raised INR 42 crores of debt related to the Unbound acquisition. The company is comfortable with this level of debt given their improved DSO (45 days). Rahul Arora mentioned that INR 100 to INR 200 crores of debt does not bother them. They do not believe in sitting on excess cash; any surplus capital not required for deployment in the next 6 to 12 months will be distributed via dividends or buybacks. No mention of any immediate future equity fundraising. Capital distribution decisions, including dividends and buybacks, will be discussed and decided at the board level. The curre

Any current/future capex/capital investment/strategic investment?

MPS Limited expects significant capital outflow over the next 6 to 12 months related to current investments and acquisitions. The company shows an appetite for growth through acquisitions, with about 60% of its growth strategy relying on inorganic growth. Recent acquisitions like Unbound Medicine involve investments planned to grow the business significantly, including geographic expansion. MPS raised INR 42 crores of debt for the Unbound Medicine acquisition but remains comfortable with this debt level. Capital distribution through dividends or buybacks will continue if there is surplus capit

Future growth expectations in sales/revenue/volumes?

Unbound's revenues currently have over 60% contribution from North America; future growth will come predominantly from markets outside North America, with North America growing at single digits. The company aims to double Unbound's revenue over the next few years by expanding into new geographies such as Southeast Asia, the Middle East, Europe, and Australia. The global healthcare AI and knowledge management market is projected to grow significantly, with the AI-driven knowledge management subsector expected to expand from $3 billion to $102 billion by 2034 at a 42% CAGR. MPS targets an

Future growth expectations in earnings/operating earnings/profits/EPS?

MPS aims for 20%-25% year-on-year growth; PBT CAGR of 21% since FY’21. Target revenue of INR 1500 crores at similar margins within a few years. Growth driven by a blend of organic and inorganic strategies; acquisitions constitute ~60% of growth plan. Segment revenue expected to evolve to approx. 40% Research, 40% Education, 20% Corporate Learning. Unbound EBITDA margin expected to increase from 14% to early 20% in Q2 FY’27, then approach MPS average of ~30% by end of FY’27. Cross-selling and geographic expansion (outside North America) anticipated to drive revenue acceleration. Margin expansio

IN US

Sale is live|00:00:00left today

MPS LtdQ4 FY27Printing & Publication

MPS Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,896P/E: 17.3Market Cap: ₹2.8K CrSector: Printing & Publication

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Unbound's revenues currently have over 60% contribution from North America; future growth will come predominantly from markets outside North America, with North America growing at single digits.
→The company aims to double Unbound's revenue over the next few years by expanding into new geographies such as Southeast Asia, the Middle East, Europe, and Australia.
→The global healthcare AI and knowledge management market is projected to grow significantly, with the AI-driven knowledge management subsector expected to expand from $3 billion to $102 billion by 2034 at a 42% CAGR.
→MPS targets an overall growth rate of 20%-25% year-on-year, blending organic and inorganic routes, with acquisitions comprising about 60% of growth strategy.
→The revenue mix is expected to evolve to roughly 40% Research, 40% Education, and 20% Corporate Learning in the coming years.
→New cross-selling opportunities between MPS and Unbound customers are expected to accelerate revenue growth.

Margin guidance

Category 1

→MPS aims for 20%-25% year-on-year growth; PBT CAGR of 21% since FY’21.
→Target revenue of INR 1500 crores at similar margins within a few years.
→Growth driven by a blend of organic and inorganic strategies; acquisitions constitute ~60% of growth plan.
→Segment revenue expected to evolve to approx. 40% Research, 40% Education, 20% Corporate Learning.
→Unbound EBITDA margin expected to increase from 14% to early 20% in Q2 FY’27, then approach MPS average of ~30% by end of FY’27.
→Cross-selling and geographic expansion (outside North America) anticipated to drive revenue acceleration.
→Margin expansion through shared infrastructure and operational efficiencies.
→Dividend payout and capital distribution (dividends/buybacks) to continue as per Board’s discretion, factoring upcoming capital outflows and comfort with current debt levels.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→MPS Limited has raised INR 42 crores of debt related to the Unbound acquisition.
→The company is comfortable with this level of debt given their improved DSO (45 days).
→Rahul Arora mentioned that INR 100 to INR 200 crores of debt does not bother them.
→They do not believe in sitting on excess cash; any surplus capital not required for deployment in the next 6 to 12 months will be distributed via dividends or buybacks.
→No mention of any immediate future equity fundraising.
→Capital distribution decisions, including dividends and buybacks, will be discussed and decided at the board level.
→The current debt level is not viewed as a blocker for continuing capital distributions.

Order book

The transcript provided on pages 1 to 18 of the MPS Limited conference call dated February 18, 2026, does not explicitly mention the current or expected order book or pending orders. The discussion primarily focuses on: - The acquisition of Unbound Medicine, Inc., USA. - Synergies and growth strategy after acquisition. - EBITDA margins and revenue projections for Unbound. - Dividend and capital distribution policies. - Market expansion and cross-selling opportunities. - AI capabilities and product offerings. No specific details or figures related to existing order books or pending orders are shared in the transcript.

Capex plans

Yes

→MPS Limited expects significant capital outflow over the next 6 to 12 months related to current investments and acquisitions.
→The company shows an appetite for growth through acquisitions, with about 60% of its growth strategy relying on inorganic growth.
→Recent acquisitions like Unbound Medicine involve investments planned to grow the business significantly, including geographic expansion.
→MPS raised INR 42 crores of debt for the Unbound Medicine acquisition but remains comfortable with this debt level.
→Capital distribution through dividends or buybacks will continue if there is surplus capital and depending on board decisions, considering expected capital outflows.
→The company is focused on continued strategic investments in AI and technology to enhance product offerings, especially in Unbound, with ongoing AI infrastructure development and integration.
→Discussions on capital redistribution (dividends and buybacks) will continue at the board level in light of shareholder feedback.

How does MPS Ltd rank vs peers in Printing & Publication?

Pro feature

1MPS Ltd

Rev 2Mar 1

See full Printing & Publication sector rankings

Want more stocks like MPS Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio